Amgen preps for key investor meeting

Sitting on $17 billion, Amgen ($AMGN) is bracing for a tense meeting with investors who want to see what the big biotech will do with its cache of cash--and whether it has anything in the pipeline that can soon follow the successful path carved out by its bone drug denosumab. Report

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.